OneDigital Investment Advisors LLC Buys Shares of 44,275 Insulet Corporation $PODD

OneDigital Investment Advisors LLC bought a new stake in Insulet Corporation (NASDAQ:PODD) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 44,275 shares of the medical instruments supplier’s stock, valued at approximately $6,741,000. OneDigital Investment Advisors LLC owned approximately 0.06% of Insulet at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in PODD. Larson Financial Group LLC increased its stake in Insulet by 114.6% in the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 47 shares during the last quarter. University of Texas Texas AM Investment Management Co. bought a new stake in Insulet during the fourth quarter worth $26,000. Elyxium Wealth LLC bought a new stake in Insulet during the fourth quarter worth $28,000. DV Equities LLC bought a new stake in Insulet during the fourth quarter worth $28,000. Finally, MV Capital Management Inc. acquired a new stake in shares of Insulet in the 4th quarter valued at $29,000.

Key Insulet News

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet remains a long-term growth story: its Omnipod wearable insulin-delivery platform supports recurring revenue, while the company recently reported 23.5% year-over-year revenue growth, earnings above analyst expectations, and raised confidence in its full-year outlook. Why Insulet Is a Top Growth Stock for the Long-Term
• Neutral Sentiment: Multiple law firms are publicizing an August 31, 2026 deadline for investors to seek lead-plaintiff status in a pending federal securities class action. The announcements mainly solicit shareholder participation and do not establish liability or damages. Insulet Securities Fraud Lawsuit Deadline Alert
• Negative Sentiment: The litigation creates a significant near-term overhang. Complaints filed by investors allege that Insulet and certain executives made materially false or misleading statements concerning manufacturing controls and the safety and reliability of its insulin-delivery products. One notice specifically cites alleged defective cannula manufacturing that could have caused insulin under-delivery in millions of Omnipod devices. If substantiated, the claims could lead to financial costs, regulatory scrutiny, reputational damage, and weaker customer confidence. Insulet Securities Class Action Allegations

Insider Buying and Selling

In other news, Director Timothy C. Stonesifer bought 2,790 shares of the company’s stock in a transaction on Wednesday, June 3rd. The stock was purchased at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the completion of the transaction, the director owned 9,041 shares of the company’s stock, valued at $1,297,473.91. This trade represents a 44.63% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 0.36% of the company’s stock.

Insulet Price Performance

Shares of NASDAQ:PODD opened at $143.34 on Monday. The company has a fifty day moving average of $155.20 and a 200-day moving average of $188.22. The company has a market capitalization of $9.94 billion, a PE ratio of 26.79, a price-to-earnings-growth ratio of 1.13 and a beta of 1.10. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.83 and a current ratio of 2.48. Insulet Corporation has a 52-week low of $126.40 and a 52-week high of $354.88.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share for the quarter, beating the consensus estimate of $1.47 by $0.19. The company had revenue of $801.70 million for the quarter, compared to the consensus estimate of $787.39 million. Insulet had a return on equity of 29.29% and a net margin of 12.29%.Insulet’s revenue for the quarter was up 23.5% on a year-over-year basis. During the same quarter last year, the business posted $1.17 EPS. Insulet has set its FY 2026 guidance at 6.460- EPS. On average, equities analysts predict that Insulet Corporation will post 6.51 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on PODD shares. Wall Street Zen lowered Insulet from a “strong-buy” rating to a “hold” rating in a research note on Sunday, August 9th. Stifel Nicolaus dropped their price objective on Insulet from $225.00 to $180.00 and set a “buy” rating for the company in a research report on Thursday, August 6th. Weiss Ratings lowered Insulet from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, June 24th. Sanford C. Bernstein decreased their target price on Insulet from $200.00 to $175.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. Finally, Rothschild & Co Redburn reissued a “neutral” rating and set a $220.00 target price (down from $380.00) on shares of Insulet in a research note on Friday, April 24th. Fourteen analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $195.40.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.